Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old

BACKGROUND: Older adults are at increased risk of adverse outcomes from pneumococcal disease and COVID-19. Vaccination is an established strategy for preventing both illnesses. This study evaluated the safety and immunogenicity of coadministration of the 20-valent pneumococcal conjugate vaccine (PCV...

Descripción completa

Detalles Bibliográficos
Autores principales: Fitz-Patrick, David, Young, Mariano, Yacisin, Kari, McElwee, Kathleen, Belanger, Todd, Belanger, Kelly, Peng, Yahong, Lee, Dung-Yang, Gruber, William C., Scott, Daniel A., Watson, Wendy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165018/
https://www.ncbi.nlm.nih.gov/pubmed/37244809
http://dx.doi.org/10.1016/j.vaccine.2023.05.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165018/
https://www.ncbi.nlm.nih.gov/pubmed/37244809
http://dx.doi.org/10.1016/j.vaccine.2023.05.002

Ejemplares similares